References
Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing’s Syndrome: a consensus statement. J Clin Endocrinol Metab 2008, 93: 2454–62.
Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotrophin hypersecretion. J Endocrinol Invest 1990, 13: 257–61.
Hofland LJ, Van Der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005, 152: 645–54.
Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009, 94: 115–22.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fiorentino, C., Motta, C., Wolosinska, D.T. et al. SOM230 in Cushing’s disease complicated by poorly controlled diabetes mellitus. J Endocrinol Invest 34, 731–732 (2011). https://doi.org/10.1007/BF03345407
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345407